Gregory Stuart Ducker portrait
  • Assistant Professor, Department Of Biochemistry
801-581-2117

Research Statement

Changes in cellular metabolism underlie many diseases. For example, cancer cells must become proliferative, requiring both increases in the production of key biosynthetic building blocks and new nutrient acquisition strategies to supply them. Research in my group focuses on understanding at a molecular level the fundamental metabolic processes underlying cellular disease physiology- what pathways and processes contribute to disease and how do cells acquire the nutrients to fuel them? One long-term goal of our research is to characterize the metabolic requirements of cancer cells and tumors in vivo in order to identify and validate new therapeutic targets. Our approach is fundamentally biochemical, based on integrating new mass spectrometry technology with CRISPR/Cas9 genetic engineering to be able to precisely quantify metabolic fluxes in vivo. By starting with a fundamentals based perspective on metabolism, we are able to apply our knowledge across different cell types and disease states providing unifying theory to diverse biological presentations.   

Research Keywords

  • Cancer Metabolism
  • Mass Spectrometry
  • Antimetabolites
  • Chemical Biology
  • Mitochondria
  • Tetrahydrofolates

Presentations

  • Ducker GS. Isotope tracing of compartmentalized folate metabolism. 7th International Symposium on Folate Receptors and Transporters, Taormina, Italy. , , 2018.
  • Ducker GS. Expanding our understanding of one-carbon metabolism in cancer. Rising Stars Symposium, Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT. , , 2017.
  • Ducker GS. Metabolomics and drug discovery in one-carbon metabolism. Discovery on Target pharmaceutical conference, Boston, MA. , , 2016.
  • Ducker GS. Mitochondrial folate metabolism in cancer. Federation of American Societies for Experimental Biology (FASEB) Science Research Conference Folic Acid, Steamboat Springs, CO. , , 2016.
  • Ducker, GS. Altered phosphatidylcholine metabolism in a β-catenin driven zebrafish model of hepatocellular carcinoma. Selected abstract for short talk at Keystone Meeting "Tumor metabolism" rescheduled for Keystone, CO. , Accepted, 2022.
  • Ducker GS. Altered phosphatidylcholine metabolism in a β-catenin driven zebrafish model of hepatocellular carcinoma. Selected short talk from abstracts at the second annual Fusion Meeting "Metabolism in health and disease", Cancun, Mexico. , Presented, 2022.
  • Ducker GS. Tracing Amino Acid Metabolism. Short talk from submitted abstracts at the FASEB conference on glucose metabolism, Palm Springs, CA. , Presented, 2019.
  • Ducker GS. Glycine restriction synergizes with inhibition of mitochondrial one-carbon metabolism to block cancer proliferation. Short talk, Keystone Symposium Tumor Metabolism, Snowbird, UT. , , 2018.
  • Ducker GS. Inhibitors of Serine Hydroxymethyltransferase Reveal a Requirement for Glycine Synthesis in Diffuse Large B-Cell Lymphoma. Short talk, New York Academy of Sciences Targeting Cancer Metabolism and Signaling symposium, New York, NY. , , 2017.
  • Ducker GS. Genetic and metabolic dissection of one-carbon metabolism. Short talk, Company of Biologists metabolism in development and disease workshop, Steyning, United Kingdom. , , 2016.
  • Ducker GS. Compartmental flexibility in mammalian folate metabolism. Short talk, American Association for Cancer Research National Meeting, Philadelphia, PA. , , 2015.
  • Ducker GS. Incomplete inhibition of phosphorylation of 4EBP1 is a mechanism for KRAS-driven resistance to the ATP-competitive mTOR inhibitor PP242 in colorectal cancer. Short talk, American Association for Cancer Research special conference: Molecularly targeted therapies: mechanisms of resistance, San Diego, CA. , , 2012.

Languages

  • English, Fluent.

Publications

  • Ducker GS, Rabinowitz JD (date unknown). ZMP: a master regulator of one-carbon metabolism. (pp. 203-4). Vol. 57. Accepted, .
  • Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK (date unknown). A patient-derived xenograft model of pancreatic neuroendocrine tumors identifies sapanisertib as a possible new treatment for everolimus-resistant tumors. Vol. 17, 2702-2709. Accepted, .
  • Bensard CL, Wisidagama DR, Olson KA, Berg JA, Krah NM, Schell JC, Nowinski SM, Fogarty S, Bott AJ, Wei P, Dove KK, Tanner JM, Panic V, Cluntun A, Lettlova S, Earl CS, Namnath DF, Vázquez-Arreguín K, Villanueva CJ, Tantin D, Murtaugh LC, Evason KJ, Ducker GS, Thummel CS, Rutter J (date unknown). Regulation of Tumor Initiation by the Mitochondrial Pyruvate Carrier. Accepted, .
  • Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM (date unknown). Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Vol. 30, 2219-25. Accepted, .
  • Ducker GS, Ghergurovich JM, Mainolfi N, Suri V, Jeong SK, Hsin-Jung Li S, Friedman A, Manfredi MG, Gitai Z, Kim H, Rabinowitz JD (date unknown). Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Vol. 114, 11404-11409. Accepted, .
  • Chen L, Ducker GS, Lu W, Teng X, Rabinowitz JD (date unknown). An LC-MS chemical derivatization method for the measurement of five different one-carbon states of cellular tetrahydrofolate. Vol. 409, 5955-5964. Accepted, .
  • Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM (date unknown). The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Vol. 108, 15201-6. Accepted, .
  • Okuzumi T, Ducker GS, Zhang C, Aizenstein B, Hoffman R, Shokat KM (date unknown). Synthesis and evaluation of indazole based analog sensitive Akt inhibitors. Vol. 6, 1389-402. Accepted, .
  • McCormick SR, McCormick MJ, Grutkoski PS, Ducker GS, Banerji N, Higgins RR, Mendiola JR, Reinartz JJ (date unknown). FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Vol. 134, 1143-51. Accepted, .
  • Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D (date unknown). Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Vol. 110, 11988-93. Accepted, .
  • Rodan L, Qi W, Ducker GS, Demirbas D, Laine R, Yang E, Walker MA, Eichler F, Rabinowitz JD, Anselm I, Berry GT (date unknown). 5,10-methenyltetrahydrofolate synthetase deficiency causes a neurometabolic disorder associated with microcephaly, epilepsy, and cerebral hypomyelination. Accepted, .
  • Ducker GS, Chen L, Morscher RJ, Ghergurovich JM, Esposito M, Teng X, Kang Y, Rabinowitz JD (date unknown). Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. Vol. 23, 1140-1153. Accepted, .
  • Rodriguez AE, Ducker GS, Billingham LK, Martinez C, Suri V, Friedman A, Manfredi M, Weinberg SE, Rabinowitz JD, Chandel NC. (date unknown). Serine metabolism supports macrophage IL-1β production. Vol. 29, 1003-1011. Accepted, .
  • Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS (date unknown). Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Vol. 33, 1590-600. Accepted, .
  • Morscher RJ, Ducker GS, Li SH, Mayer JA, Gitai Z, Sperl W, Rabinowitz JD (date unknown). Mitochondrial translation requires folate-dependent tRNA methylation. Vol. 554, 128-132. Accepted, .
  • Davies JM, Robinson AE, Cowdrey C, Mummaneni PV, Ducker GS, Shokat KM, Bollen A, Hann B, Phillips JJ (date unknown). Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. Vol. 120, 331-6. Accepted, .
  • Dekhne A, Shah K, Ducker GS, Katinas JM, Wong J, Nayeen MJ, Doshi A, Ning C, Bao X, Frühauf J, Wallace-Povirk A, O’Connor C, Dzinic S, White K, Kushner J, Kim S, Polin L, Rabinowitz JD, Li J, Hou Z, Dann III CE, Gangjee A, Matherly LM. (date unknown). Novel pyrrolopyrimidine compounds inhibit mitochondrial and cytosolic one-carbon metabolism with broad-spectrum anti-tumor efficacy. Accepted, .
  • Li AM, Ducker GS, Li Y, Seoane JA, Xiao Y, Melemenidis S, Zhou Y, Liu L, Vanharanta S, Graves EE, Rankin EB, Curtis C, Massague J, Rabinowitz JD, Thompson CB, Ye J (date unknown). Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. Accepted, .
  • Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP (date unknown). Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. Vol. 13, e0193849. Accepted, .
  • Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK (date unknown). A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Vol. 17, 2702-2709. Accepted, .
  • Dekhne AS, Shah K, Ducker GS, Katinas JM, Wong-Roushar J, Nayeen MJ, Doshi A, Ning C, Bao X, Frühauf J, Liu J, Wallace-Povirk A, O'Connor C, Dzinic SH, White K, Kushner J, Kim S, Hüttemann M, Polin L, Rabinowitz JD, Li J, Hou Z, Dann CE 3rd, Gangjee A, Matherly LH (date unknown). Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy. Vol. 18, 1787-1799. Accepted, .
  • Rodan LH, Qi W, Ducker GS, Demirbas D, Laine R, Yang E, Walker MA, Eichler F, Rabinowitz JD, Anselm I, Berry GT, Undiagnosed Diseases Network (UDN). (date unknown). 5,10-methenyltetrahydrofolate synthetase deficiency causes a neurometabolic disorder associated with microcephaly, epilepsy, and cerebral hypomyelination. Vol. 125, 118-126. Accepted, .
  • Panic V, Pearson S, Banks J, Tippetts TS, Velasco-Silva JN, Lee S, Simcox J, Geoghegan G, Bensard CL, van Ry T, Holland WL, Summers SA, Cox J, Ducker GS, Rutter J, Villanueva CJ (date unknown). Mitochondrial pyruvate carrier is required for optimal brown fat thermogenesis. Vol. 9. Accepted, .
  • Rodriguez AE, Ducker GS, Billingham LK, Martinez CA, Mainolfi N, Suri V, Friedman A, Manfredi MG, Weinberg SE, Rabinowitz JD, Chandel NS (date unknown). Serine Metabolism Supports Macrophage IL-1β Production. Vol. 29, 1003-1011.e4. Accepted, .
  • Cluntun AA, Badolia R, Lettlova S, Parnell KM, Shankar TS, Diakos NA, Olson KA, Taleb I, Tatum SM, Berg JA, Cunningham CN, Van Ry T, Bott AJ, Krokidi AT, Fogarty S, Skedros S, Swiatek WI, Yu X, Luo B, Merx S, Navankasattusas S, Cox JE, Ducker GS, Holland WL, McKellar SH, Rutter J, Drakos SG (date unknown). The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Vol. 33, 629-648.e10. Accepted, .
  • Ducker GS, Rabinowitz JD (date unknown). One-Carbon Metabolism in Health and Disease. (pp. 27-42). Vol. 25. Accepted, .